Results 181 to 190 of about 1,281 (194)

A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis

Arthritis &Rheumatology, Accepted Article.
Background Individuals with serum elevations of anti‐cyclic citrullinated peptide (anti‐CCP) antibodies are at increased risk for future rheumatoid arthritis (RA). No pharmacologic interventions have been approved for the prevention of RA in such ‘at‐risk’ individuals. However, hydroxychloroquine (HCQ) is used without supporting clinical trial evidence.
Kevin D. Deane, Christopher C. Striebich, Marie L. Feser, James R. O'Dell, Judith A. James, Jeffrey A. Sparks, John M. Davis, Jonathan Graf, Maureen A. McMahon, Elizabeth B. Solow, Lindsy Forbess, Athan Tiliakos, Elena Schiopu, Maria I. Danila, Diane L. Horowitz, Jonathan Kay, Colin D. Strickland, Joel M. Guthridge, Cristina Arriens, Jennifer M. Grossman, M. Kristen Demoruelle, Elizabeth A. Bemis, Ashley Frazer‐Abel, Chelsie L. Fleischer, David A. Fox, Ted R. Mikuls, Melissa Greenleaf, Kate York, Sarah Walker, Lynette Keyes‐Elstein, Margie Byron, Janel Fedler, Ellen A. Goldmuntz, V. Michael Holers   +33 more
wiley   +1 more source

Distinct HLA Associations for Antibody Multireactivity With Citrulline‐Containing Type II Collagen Epitopes Versus More Limited Antibody Reactivity With Citrulline‐Containing IgG Epitopes in Rheumatoid Arthritis

Arthritis &Rheumatology, EarlyView.
Objective Anticitrullinated protein antibodies (ACPAs) in rheumatoid arthritis (RA) can be promiscuous, with cross‐reactive binding to many antigens containing short motifs, or private with little cross‐reactivity. Also, ACPA reactivity patterns differ among patients with RA, including for motif‐containing epitopes in important self‐antigens like ...
S. Janna Bashar, Courtney B. Myhr, Adam H. Titi, Zihao Zheng, Miriam A. Shelef   +4 more
wiley   +1 more source

Identification of histone deacetylase inhibitor targeting type I interferon and B‐cell abnormalities in systemic lupus erythematosus

Arthritis &Rheumatology, Accepted Article.
Objective Systemic lupus erythematosus (SLE) is characterized by increased type I interferon (IFN‐I) and autoantibody production. This study aimed to identify drugs that can inhibit both IFN‐I and autoantibody production. Methods We identified an inhibitor of IFN‐I production from a chemical library.
Takehiro Hirayama, Hachiro Konaka, Yasuhiro Kato, Takayuki Shibahara, Chisato Nishizawa, Kohei Tsujimoto, JeongHoon Park, Eri Itotagawa, Tatsunori Jo, Masayuki Nishide, Sumiyuki Nishida, Yoshihito Shima, Masashi Narazaki, Wataru Aoki, Ken J Ishii, Hyota Takamatsu, Atsushi Kumanogoh   +16 more
wiley   +1 more source

Immunologic Profiling Suggests an Association Between Treg Cell Dysfunction and Pain in Knee Osteoarthritis

Arthritis &Rheumatology, EarlyView.
Objective Pain is the hallmark symptom of osteoarthritis (OA), and its biologic drivers remain poorly understood. Although the role of innate immunity in OA has been extensively studied, the involvement of adaptive immunity, in particular Treg cells, is not well understood.
Marie Binvignat, Johanna Dubois, Maria Marco Salvador, Paul Stys, Fabien Pitoiset, Alexandra Roux, Michèle Sastre, Signe Hassler, Roberta Lorenzon, Claire Ribet, Vanessa Mhanna, Hélène Vantomme, Leslie Adda, Pierre Barennes, Nicolas Coatnoan, Kenz Le Gouge, Caroline Aheng, Alice Courties, Lise Minssen, Atul J. Butte, Adrien Six, Michelle Rosenzwajg, Nicolas Tchitchek, Francis Berenbaum, David Klatzmann, Encarnita Mariotti‐Ferrandiz, Jérémie Sellam   +26 more
wiley   +1 more source

Plasma Proteomics Identifies TAOK3 as a Potential Biomarker of Rheumatoid Arthritis Activity and a Novel Therapeutic Target

Arthritis &Rheumatology, Accepted Article.
Objective Bone destruction associated with active rheumatoid arthritis (RA) remains a major therapeutic challenge, with a lack of reliable molecular markers reflecting bone injury. This study aims to identify novel biomarkers linked to bone destruction in active RA through proteomic analysis, providing new strategies for precise monitoring and targeted
Pengfei Xin, Wenzhen Li, Xinyu A, Jun Shen, Xiaohui Meng, Yanqin Bian, Haihui Han, Zheng Xiang, Lei Ran, Songtao Sun, Jun Xie, Tao Yue, Qi Zhu, Xiaoming Zhang, Lu Xie, Lianbo Xiao   +15 more
wiley   +1 more source

Interleukin‐18 levels are associated with disease course in patients with Still's disease treated with IL‐1 inhibitors

Arthritis &Rheumatology, Accepted Article.
Objective To evaluate the prognostic utility of circulating Interleukin‐18 (IL‐18) levels in predicting disease activity, macrophage activation syndrome (MAS), and disease course in Still's disease (SD) patients receiving first‐line IL‐1 inhibitors (IL‐1i).
Matteo Trevisan, Manuela Pardeo, Ivan Caiello, Claudia Bracaglia, Arianna de Matteis, Valentina Matteo, Elena Loricchio, Fabrizio De Benedetti, Giusi Prencipe   +8 more
wiley   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases

Arthritis &Rheumatology, Accepted Article.
Objective GLP‐1 receptor agonists (GLP‐1RAs) and SGLT2 inhibitors (SGLT2is) facilitate weight loss and exhibit immunomodulatory effects, but their impact on the risk of developing autoimmune rheumatic diseases (ARDs) is unclear. We compared ARD incidence following initiation of GLP‐1RAs, or SGLT2is, vs.
Derin Karacabeyli, Diane Lacaille, Na Lu, Hui Xie, J. Antonio Aviña‐Zubieta   +4 more
wiley   +1 more source

Measuring the Impact: MRI Response of Sacroiliac Joints to TNF Inhibitors in Youth with Axial Disease

Arthritis &Rheumatology, Accepted Article.
Objective To evaluate the timeline for resolution of sacroiliac joint (SIJ) inflammation, changes in structural lesions, and their correlation with patient‐reported outcomes in youth with axial juvenile spondyloarthritis (axJSpA) initiating TNF inhibitor (TNFi).
Timothy G. Brandon, Rui Xiao, Daniel J. Lovell, Edward Oberle, Matthew L. Stoll, Nancy A. Chauvin, Michael L. Francavilla, Walter P. Maksymowych, Pamela F. Weiss   +8 more
wiley   +1 more source

Serum Proteomic Signatures of RA Risk and Response: Analysis of the APIPPRA Trial

Arthritis &Rheumatology, Accepted Article.
Objective To identify serum protein signatures associated with progression to rheumatoid arthritis (RA) and response to abatacept in at‐risk individuals. Methods A total of 440 serum samples from 118 APIPPRA study participants were selected from baseline to RA onset for 46 RA progressors or to study end for 72 participants who did not develop RA ...
Marianna Jasenecova, Carl Coyle, Alina Mihalovits, Sarah Ryan, Elizabeth Pook, Esperanza Perucha, Gabrielle Harker, Melody Chin, Sam Norton, Andrew P. Cope   +9 more
wiley   +1 more source

Anatomy in Cuvier's Paris: Broadening participation through an international research program for historically minoritized undergraduates

Anatomical Sciences Education, EarlyView.
Abstract Most research programs recruit students with high grades, previous lab experience, and strong supervisor recommendations. However, these requirements can bar students from historically marginalized backgrounds from gaining these kinds of valuable experiences, thus contributing to the well documented limited diversity in science, technology ...
Jacqueline Cerda‐Smith, Ashley R. Deutsch, Adam Hartstone‐Rose   +2 more
wiley   +1 more source